India · Delayed Price · Currency is INR Marksans Pharma Statistics
Total Valuation
Marksans Pharma has a market cap or net worth of INR 139.44 billion. The enterprise value is 133.20 billion.
| Market Cap | 139.44B |
| Enterprise Value | 133.20B |
Important Dates
The last earnings date was Wednesday, November 4, 2026.
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | Aug 20, 2026 |
Share Statistics
Marksans Pharma has 453.16 million shares outstanding. The number of shares has decreased by -0.06% in one year.
| Current Share Class | 453.16M |
| Shares Outstanding | 453.16M |
| Shares Change (YoY) | -0.06% |
| Shares Change (QoQ) | +0.32% |
| Owned by Insiders (%) | 43.87% |
| Owned by Institutions (%) | 12.66% |
| Float | 214.42M |
Valuation Ratios
The trailing PE ratio is 24.91 and the forward PE ratio is 22.82. Marksans Pharma's PEG ratio is 0.88.
| PE Ratio | 24.91 |
| Forward PE | 22.82 |
| PS Ratio | 4.06 |
| PB Ratio | 4.09 |
| P/TBV Ratio | 4.48 |
| P/FCF Ratio | 22.92 |
| P/OCF Ratio | 19.56 |
| PEG Ratio | 0.88 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 16.79, with an EV/FCF ratio of 21.88.
| EV / Earnings | 23.49 |
| EV / Sales | 3.88 |
| EV / EBITDA | 16.79 |
| EV / EBIT | 19.39 |
| EV / FCF | 21.88 |
Financial Position
The company has a current ratio of 5.02, with a Debt / Equity ratio of 0.14.
| Current Ratio | 5.02 |
| Quick Ratio | 3.14 |
| Debt / Equity | 0.14 |
| Debt / EBITDA | 0.59 |
| Debt / FCF | 0.77 |
| Interest Coverage | 26.01 |
Financial Efficiency
Return on equity (ROE) is 18.60% and return on invested capital (ROIC) is 19.99%.
| Return on Equity (ROE) | 18.60% |
| Return on Assets (ROA) | 10.87% |
| Return on Invested Capital (ROIC) | 19.99% |
| Return on Capital Employed (ROCE) | 18.04% |
| Weighted Average Cost of Capital (WACC) | 10.14% |
| Revenue Per Employee | 20.13M |
| Profits Per Employee | 3.32M |
| Employee Count | 1,685 |
| Asset Turnover | 0.87 |
| Inventory Turnover | 1.54 |
Taxes
In the past 12 months, Marksans Pharma has paid 1.85 billion in taxes.
| Income Tax | 1.85B |
| Effective Tax Rate | 24.65% |
Stock Price Statistics
The stock price has increased by +67.72% in the last 52 weeks. The beta is 1.11, so Marksans Pharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.11 |
| 52-Week Price Change | +67.72% |
| 50-Day Moving Average | 318.78 |
| 200-Day Moving Average | 244.56 |
| Relative Strength Index (RSI) | 48.33 |
| Average Volume (20 Days) | 1,303,425 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Marksans Pharma had revenue of INR 33.92 billion and earned 5.60 billion in profits. Earnings per share was 12.35.
| Revenue | 33.92B |
| Gross Profit | 18.91B |
| Operating Income | 6.78B |
| Pretax Income | 7.51B |
| Net Income | 5.60B |
| EBITDA | 7.47B |
| EBIT | 6.78B |
| Earnings Per Share (EPS) | 12.35 |
Balance Sheet
The company has 11.24 billion in cash and 4.65 billion in debt, with a net cash position of 6.59 billion or 14.54 per share.
| Cash & Cash Equivalents | 11.24B |
| Total Debt | 4.65B |
| Net Cash | 6.59B |
| Net Cash Per Share | 14.54 |
| Equity (Book Value) | 33.67B |
| Book Value Per Share | 73.57 |
| Working Capital | 24.12B |
Cash Flow
In the last 12 months, operating cash flow was 7.04 billion and capital expenditures -1.03 billion, giving a free cash flow of 6.01 billion.
| Operating Cash Flow | 7.04B |
| Capital Expenditures | -1.03B |
| Depreciation & Amortization | 689.36M |
| Net Borrowing | -441.51M |
| Free Cash Flow | 6.01B |
| FCF Per Share | 13.26 |
Margins
Gross margin is 55.74%, with operating and profit margins of 20.00% and 16.51%.
| Gross Margin | 55.74% |
| Operating Margin | 20.00% |
| Pretax Margin | 22.13% |
| Profit Margin | 16.51% |
| EBITDA Margin | 22.03% |
| EBIT Margin | 20.00% |
| FCF Margin | 17.72% |
Dividends & Yields
This stock pays an annual dividend of 0.90, which amounts to a dividend yield of 0.29%.
| Dividend Per Share | 0.90 |
| Dividend Yield | 0.29% |
| Dividend Growth (YoY) | 12.50% |
| Years of Dividend Growth | 3 |
| Payout Ratio | 7.29% |
| FCF Payout Ratio | 6.79% |
| Buyback Yield | 0.06% |
| Shareholder Yield | 0.36% |
| Earnings Yield | 4.02% |
| FCF Yield | 4.36% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside |
Analyst Forecast
The average price target for Marksans Pharma is 324.33, which is 5.41% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 324.33 |
| Price Target Difference | 5.41% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 17.81% |
| EPS Growth Forecast (3Y) | 25.90% |
Stock Splits
The last stock split was on March 11, 2008. It was a forward split with a ratio of 10.
| Last Split Date | Mar 11, 2008 |
| Split Type | Forward |
| Split Ratio | 10 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 6 |